NRX Pharmaceuticals Inc has a consensus price target of $3, established from looking at the 4 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Ascendiant Capital on May 25, 2023, February 2, 2023, and November 9, 2022. With an average price target of $2.67 between HC Wainwright & Co., HC Wainwright & Co., and Ascendiant Capital, there's an implied -12.57% downside for NRX Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
05/25/2023 | NRXP | Buy Now | NRX Pharmaceuticals | $3.05 | -34.43% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Reiterates | Buy → Buy | Get Alert |
02/02/2023 | NRXP | Buy Now | NRX Pharmaceuticals | $3.05 | -34.43% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Reiterates | → Buy | Get Alert |
11/09/2022 | NRXP | Buy Now | NRX Pharmaceuticals | $3.05 | 31.15% | Ascendiant Capital | Edward Woo | → $40 | Initiates | → Buy | Get Alert |
06/30/2022 | NRXP | Buy Now | NRX Pharmaceuticals | $3.05 | -34.43% | HC Wainwright & Co. | Vernon Bernardino | → $20 | Initiates | → Buy | Get Alert |
The latest price target for NRX Pharmaceuticals (NASDAQ: NRXP) was reported by HC Wainwright & Co. on May 25, 2023. The analyst firm set a price target for $2.00 expecting NRXP to fall to within 12 months (a possible -34.43% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for NRX Pharmaceuticals (NASDAQ: NRXP) was provided by HC Wainwright & Co., and NRX Pharmaceuticals reiterated their buy rating.
There is no last upgrade for NRX Pharmaceuticals.
There is no last downgrade for NRX Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NRX Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NRX Pharmaceuticals was filed on May 25, 2023 so you should expect the next rating to be made available sometime around May 25, 2024.
While ratings are subjective and will change, the latest NRX Pharmaceuticals (NRXP) rating was a reiterated with a price target of $0.00 to $2.00. The current price NRX Pharmaceuticals (NRXP) is trading at is $3.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.